Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS)
- PMID: 17130899
- DOI: 10.1038/sj.icb.7100008
Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS)
Abstract
The past four decades has witnessed a consolidation of the original observations made in the 1970s that dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS) have an immunological basis. Following reinfection with a dengue virus of different serotype, severe disease is linked to high levels of antibody-enhanced viral replication early in illness which is followed by a cascade of memory T-cell activation and a 'storm' of inflammatory cytokines and other chemical mediators. These compounds are released mainly from T cells, monocytes/macrophages and endothelial cells, and ultimately cause an increase in vascular permeability. The consolidation of the evidence has been largely due to several important prospective sero-epidemiological studies in areas endemic for DHF/DSS, which have shown that risk of severe disease is significantly higher in secondary dengue infections. These advances have underscored the fact that DHF/DSS pathogenesis is a complex, multifactorial process involving cocirculation of various dengue virus serotypes and the interplay of host and viral factors that influence disease severity. The continued search to define risk factors in susceptible populations must be combined with the new techniques of molecular virology and innovative approaches in vaccine design to achieve the ultimate objective of developing a safe and effective vaccine.
Similar articles
-
The pathology of dengue hemorrhagic fever.Semin Diagn Pathol. 2007 Nov;24(4):227-36. doi: 10.1053/j.semdp.2007.07.002. Semin Diagn Pathol. 2007. PMID: 18085063 Review.
-
Dengue fever and dengue haemorrhagic fever: challenges of controlling an enemy still at large.Rev Med Virol. 2001 Sep-Oct;11(5):301-11. doi: 10.1002/rmv.324. Rev Med Virol. 2001. PMID: 11590668 Review.
-
Autoimmune pathogenesis in dengue virus infection.Viral Immunol. 2006 Summer;19(2):127-32. doi: 10.1089/vim.2006.19.127. Viral Immunol. 2006. PMID: 16817755 Review.
-
Antibody avidity following secondary dengue virus type 2 infection across a range of disease severity.J Clin Virol. 2015 Aug;69:63-7. doi: 10.1016/j.jcv.2015.06.003. Epub 2015 Jun 5. J Clin Virol. 2015. PMID: 26209381 Free PMC article.
-
Dengue virus non-structural protein 1: a pathogenic factor, therapeutic target, and vaccine candidate.J Biomed Sci. 2018 Jul 24;25(1):58. doi: 10.1186/s12929-018-0462-0. J Biomed Sci. 2018. PMID: 30037331 Free PMC article. Review.
Cited by
-
Updates in the Management of Dengue Shock Syndrome: A Comprehensive Review.Cureus. 2023 Oct 9;15(10):e46713. doi: 10.7759/cureus.46713. eCollection 2023 Oct. Cureus. 2023. PMID: 38021722 Free PMC article. Review.
-
Viremia and Inflammatory Cytokines in Dengue: Interleukin-2 as a Biomarker of Infection, and Interferon-α and -γ as Markers of Primary versus Secondary Infection.Pathogens. 2023 Nov 17;12(11):1362. doi: 10.3390/pathogens12111362. Pathogens. 2023. PMID: 38003826 Free PMC article.
-
Functional and transcriptional heterogeneity within the massively expanding HLADR+CD38+ CD8 T cell population in acute febrile dengue patients.J Virol. 2023 Nov 30;97(11):e0074623. doi: 10.1128/jvi.00746-23. Epub 2023 Oct 19. J Virol. 2023. PMID: 37855600 Free PMC article.
-
Antibody-Dependent Enhancement with a Focus on SARS-CoV-2 and Anti-Glycan Antibodies.Viruses. 2023 Jul 20;15(7):1584. doi: 10.3390/v15071584. Viruses. 2023. PMID: 37515270 Free PMC article. Review.
-
Mathematical modeling of Dengue virus serotypes propagation in Mexico.PLoS One. 2023 Jul 14;18(7):e0288392. doi: 10.1371/journal.pone.0288392. eCollection 2023. PLoS One. 2023. PMID: 37450471 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
